Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders France17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Finland17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Spain17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Denmark17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Germany17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Czech Republic17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Switzerland17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Belgium17711971.6Filed on 2018-09-11
Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders Austria17711971.6Filed on 2018-09-11
DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF Read more about DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF European Patent21158632.6Filed on 2021-02-23
